2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 252-254
Treatment Considerations, Biological Therapies, Antibody Therapy, Adverse Events, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Infectious Diseases, Other Pathogens, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

463 Prospective association of steady-state dehydration with acute vaso-occlusive episodes in adults with sickle cell disease

Melissa C. Caughey, PhD, Julia Z Xu, MD, MScGH2, Lynda Little-Ihrig3, Manzoor Mohideen4, Ana Catharina Joaquim, MD5, Michele Ly6, Jude Jonassaint, RN7, Pooja Amarapurkar8, Matthew Karafin, MD9, Enrico M Novelli, MD10
1 Johns Hopkins School of Medicine, Baltimore, Maryland, United States
2 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
3 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
4 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
6 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
7 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
8 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
9 University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States
10 University of Maryland School of Medicine, Baltimore, Maryland, United States

Background: Acute, extreme dehydration is a known trigger for sickle cell vaso-occlusive episodes (VOE), and daily fluid intake requirements are recommended for preventive care. However, attaining normal hydration status is likely to be complicated by hyposthenuria, and mild dehydration during steady state (non-VOE conditions) may be common in patients with sickle cell disease (SCD). Whether steady-state dehydration is associated with future risk of acute crisis is uncertain.

Methods: We evaluated the prevalence of steady state dehydration in adult participants of the Cooperative Study of Sickle Cell Disease Continuation Study (CSSCD, n=84, study years: 1989-1993) and the Multicenter Study of Hydroxyurea Patients’ Follow Up study (MSH, n=171, study years: 1996-2000), who had existing frozen serum specimens at the study completion. Remaining blood specimens were stored in -80C freezers maintained by the NHLBI BioLINCC repository. We assayed serum osmolality with quality assurance controls, using a low volume (30 µL) osmometer (Precision Instruments Micro-Osmette 6002). Steady state dehydration was defined by a serum osmolality >295 mOsm/kg. Prospective VOEs were available in the CSSCD Continuation Study that followed participants for acute pain events necessitating medical attention. Events were classified and adjudicated by standardized review. The associations of baseline steady state dehydration with incident number of acute pain events were analyzed using multivariable Poisson regression, with follow up time as the offset. Models were adjusted for age, sex, and comorbid conditions known to influence serum osmolality (chronic kidney disease, and diabetes).

Results: The CSSCD was an observational cohort study, while the MSH was a clinical trial that enriched for unstable SCD. Our assayed CSSCD population was older than our MSH population (mean age: 52 vs. 33 years), more predominantly female (74% vs. 50%), and included not only the HbSS genotype but also HbSC (32%) and HbS/β+(6%), which were excluded from the MSH. Despite these differences, the prevalence of steady-state dehydration was comparable (35% and 27%). When the cohorts were pooled, steady state dehydration was associated with older age (mean 42 vs. 38 years, p=0.01) but not sex. Coinherited alpha thalassemia was significantly less common in participants with steady state dehydration than those without (20% vs. 32%, p=0.04). Acute pain events were surveilled across a median 3.2 years of follow-up in the CSSCD Continuation Study. The number of events ranged from 0 to 57 for participants with baseline dehydration, and from 0 to 21 for those without, amounting to annualized event rates of 1.76/year and 0.45/year. Baseline steady-state dehydration was associated with over 4 times the incidence of acute pain (adjusted incidence rate ratio [IRR] = 4.46; 95% CI: 2.05 – 9.67; p=0.0002), corresponding to an incidence rate difference (IRD) of 1.32 (95% CI: 0.50 – 2.14; p=0.002) extra events per year than participants without steady state-dehydration. The associations persisted after additional adjustment for alpha thalassemia and SCD genotype (IRR = 3.38 [1.51 – 7.55]; p=0.003) and (IRD = 0.94 [0.19 – 1.69]; p=0.01).

Conclusion: In adults with SCD, steady-state dehydration may signify increased risk of acute clinical events. Whether this risk can be ameliorated by hydration status monitoring or interventions to optimize fluid intake is uncertain, but these strategies should be evaluated in a well-designed clinical trial.

Melissa C. Caughey, PhD: No relevant conflicts of interest to declare.